Jenburkt Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 524731 | NSE: | Pharmaceuticals & Drugs | Small Cap

Jenburkt Pharma Share Price

687.25 -11.75 -1.68%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Jenburkt Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Jenburkt Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
12.45
Market Cap:
304.3 Cr.
52-wk low:
586.9
52-wk high:
925

Is Jenburkt Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Jenburkt Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jenburkt Pharmaceuticals Ltd is a good quality company.

2. Is Jenburkt Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Jenburkt Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Jenburkt Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jenburkt Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Jenburkt Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jenburkt Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 28.9%28.5%25.5%25.8%28.2%27.5%17.8%18%19.8%19.6%-
Value Creation
Index
1.11.00.80.81.01.00.30.30.40.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 76.285.293.6103115123119109124137138
Sales YoY Gr.-11.8%9.8%10.4%11%7%-3.1%-8.1%13.4%10.3%-
Adj EPS 15.720.722.928.936.943.231.835.647.954.455.4
YoY Gr.-31.7%10.5%26.3%27.7%17%-26.3%11.8%34.5%13.6%-
BVPS (₹) 58.771.986.4117.1133.5168.8174.3214.6255.8277.3307.7
Adj Net
Profit
7.39.610.613.41719.814.616.3222424
Cash Flow from Ops. 11.48.77.81016.2131519.59.317.1-
Debt/CF from Ops. 0.20.80.70.600.60.20.20.60.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.7%3.6%4.8%10.3%
Adj EPS 14.8%8.1%19.5%13.6%
BVPS18.8%15.8%16.7%8.4%
Share Price 22.5% 6.4% 20.1% 4.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
29.331.728.928.429.328.618.618.320.42018.9
Op. Profit
Mgn %
15.117.917.619.120.720.416.618.22222.222.2
Net Profit
Mgn %
9.611.311.41314.816.212.31517.717.617.7
Debt to
Equity
0.10.20.10.100.1000.10-
Working Cap
Days
867371656984101129177185101
Cash Conv.
Cycle
3834383739567162464381

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 19.54%

Return on Equity has declined versus last 3 years average to 18.90%

Sales growth has been subdued in last 3 years 4.78%

Sales growth is not so good in last 4 quarters at 7.03%

Latest Financials - Jenburkt Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 55.4 -
TTM Sales (₹ Cr.) 138 -
BVPS (₹.) 307.7 -
Reserves (₹ Cr.) 131 -
P/BV 2.24 -
PE 12.45 -
From the Market
52 Week Low / High (₹) 586.90 / 925.00
All Time Low / High (₹) 1.80 / 925.00
Market Cap (₹ Cr.) 304
Equity (₹ Cr.) 4.4
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Jenburkt Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Jenburkt Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales768594103115123119109124137
Operating Expenses 657077849198998997106
Manufacturing Costs4554555467
Material Costs24232528313330282729
Employee Cost 17192125283137323639
Other Costs 20232526272828252632
Operating Profit 12151620242520202730
Operating Profit Margin (%) 15.1%17.9%17.6%19.1%20.7%20.3%16.6%18.2%22.0%22.2%
Other Income 2233334455
Interest 1000001000
Depreciation 2322212222
Exceptional Items 0000000000
Profit Before Tax 10141720252721223033
Tax 3567876588
Profit After Tax 8101114172015172225
PAT Margin (%) 9.8%11.3%11.5%13.1%15.0%16.1%12.5%15.1%18.0%18.0%
Adjusted EPS (₹)16.120.823.229.137.543.132.436.048.655.8
Dividend Payout Ratio (%)32%30%31%28%24%24%25%28%25%26%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 2733405461778098117122
Share Capital 5555555554
Reserves 2329365057737594113118
Minority Interest0000000000
Debt2756073462
Long Term Debt0000000000
Short Term Debt2756073462
Trade Payables4436475576
Others Liabilities 1117910121116141210
Total Liabilities 4461587678103104120143141

Fixed Assets

Gross Block24232625262731323334
Accumulated Depreciation11121315161720212224
Net Fixed Assets14121211101012111110
CWIP 0000010001
Investments 00125547811
Inventories78811710118108
Trade Receivables5769132318141517
Cash Equivalents 17283042415258574954
Others Assets1622222254940
Total Assets 4461587678103104120143141

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 11981016131519917
PBT 10141720252721223033
Adjustment 11-1-1-2-2-1-2-2-2
Changes in Working Capital 2-2-3-31-515-11-6
Tax Paid -3-5-6-7-8-7-5-6-8-8
Cash Flow From Investing Activity 010-101-11-3-19-13
Capex -1-1-200-2-4-1-3-2
Net Investments 00032-2-11-2-21-43
Others 123-41332452
Cash Flow From Financing Activity -71-51-18-2-11-1-6-21
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -100000-100-1
Dividend Paid -2-3-30-7-1-90-5-5
Others -34-21-11-1-2-1-1-15
Net Cash Flow 51121-10103-1
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)30.0531.7729.2828.5529.7528.5418.8918.4920.6620.53
ROCE (%)40.9442.3540.1739.2641.9936.925.7323.8326.8926.8
Asset Turnover Ratio1.671.651.61.561.491.361.150.970.940.96
PAT to CFO Conversion(x)1.380.90.730.710.940.6511.120.410.68
Working Capital Days
Receivable Days27272526345363534343
Inventory Days34303033282532312624
Payable Days55625161595971657884

Jenburkt Pharmaceuticals Ltd Stock News

Jenburkt Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Jenburkt Pharma on 28-Mar-2024 16:01 is ₹687.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Jenburkt Pharma stood at ₹304.3.
The latest P/E ratio of Jenburkt Pharma as of 28-Mar-2024 16:01 is 12.45.
The latest P/B ratio of Jenburkt Pharma as of 28-Mar-2024 16:01 is 2.24.
The 52-week high of Jenburkt Pharma is ₹925.0 and the 52-week low is ₹586.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jenburkt Pharma is ₹138.3 ( Cr.) .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations

The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.

The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.

Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Product range of the company includes: 

Consumer Division:

  • Nocal Tablets
  • Nocal Sachet   
  • Nocal Granular 

Pharmaceutical Division: 

  • Anti-Arthritic
  • Antibiotics 
  • Anti-Diabetic 
  • Nutraceuticals 
  • Anti-Inflammory Analgesics 
  • Gastro Intenstinal 
  • Dermatologicals
  • Aphrodisiac 
  • Anti-Osteoporotic
  • Anti-Cough, Cold & Allergy
  • Anti-Ulcerants

Awards

2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.